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(imiquimod, podofilox) and other treatments are
needed. Products for home use are relatively expen-
sive: a 1-month supply of imiquimod costs approxi-
mately $150; a 1-month supply of podofilox, $110 to
$130. These are average wholesale prices, rounded
to the nearest $10, as of Feb. 15, 2002. 
RECOMMENDATIONS FROM OTHERS
The CDC endorses podophyllin, bi- and tri-
chloroacetic acid, podofilox, imiquimod, cryothera-
py, intralesional interferon, electrosurgery, laser
surgery, and surgical excision.8 A United Kingdom
guideline on anogenital warts recommends physical
ablative methods such as cryotherapy and surgical
options for keratinized lesions and topical medica-
tions for soft lesions. The guideline also recom-
mends ablative therapy for persons with a small
number of warts regardless of type. Interferon and
5-FU are not recommended.9
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CLEARANCE RATES  REPORTED IN CLINICAL TRIALS
Therapy Clearance Rate (%)
Cryotherapy 63–-88
Electrosurgery 61–94
Imiquimod 37–56
Interferon (topical) 6–90
Interferon (intralesional) 17–63
Laser surgery 23–52
Podofilox 45–77
Podophyllin 32–79
Surgical excision 35–72
Trichloroacetic acid 50–81
Placebo or no treatment 0–56
C L I N I C A L  I N Q U I R I E S
What is the most effective treatment 
for external genital warts?
EVIDENCE-BASED ANSWER
Podofilox (Condylox), imiquimod (Aldara), cryother-
apy, and surgical options all seem reasonable alterna-
tives that are superior to podophyllin. (Grade of rec-
ommendation: B, based on systematic review.)  No
studies of surgical options versus home use prepara-
tions have been reported. Trichloroacetic acid and 5-
fluorouracil (5-FU) have not been sufficiently studied. 
EVIDENCE SUMMARY
Nonsurgical treatments that are beneficial in eradicat-
ing genital warts are podofilox (Condylox) (8 ran-
domized controlled trials [RCTs] with 1035 partici-
pants), imiquimod (Aldara) (2 RCTs with 968 partici-
pants), and intralesional interferon (8 RCTs).
Cryotherapy is equivalent to trichloroacetic acid1,2 and
electrosurgery.3 Although surgical treatments have
not been compared with placebo or no treatment,
both electrosurgery and surgical excision are superi-
or to podophyllin in clinical trials.4,5 Laser surgery is
as effective as surgical excision.6 Studies of topical
interferon show conflicting results.7 Systemic interfer-
on is not beneficial.7 Topical 5-FU has not been stud-
ied with RCTs. Wart clearance rates are summarized in
the Table. Treatment duration for nonsurgical options
is 4 to 8 weeks. Treatment of genital warts has not
been shown to reduce transmission to sex partners.7
Two RCTs4,5 showed more frequent recurrence
with podophyllin (60% to 65%) than with surgical
excision (19% to 20%). Another trial1 showed recur-
rence in 22% of participants receiving electrosurgery,
in 21% of those receiving cryotherapy, and in 44% of
those receiving podophyllin treatment. Data are lack-
ing on recurrence rates with imiquimod, podofilox,
and intralesional interferon.
Pain occurs in less than 20% of people with
imiquimod, cryotherapy, podophyllin, and electro-
surgery; 39% with topical interferon; 44% with elec-
trosurgery; 75% with podofilox; and 100% with sur-
gical excision or laser surgery.7 However, pain has
been measured using methods that are unlikely to be
comparable across studies. Flulike symptoms,
leukopenia, thrombocytopenia, and elevated aspar-
tate transaminase levels are associated with intra-
lesional interferon.7 Topical medications have not
been studied in pregnant patients. Cryotherapy is
safe in pregnancy based on case series, if only 3 or
4 treatments are given.7
Direct comparisons between home therapies
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